Ongoing studies are investigating the role of VEGFR‐3 and VEGF‐C/‐D in tumour lymphangiogenesis, using soluble VEGFR‐3 or antibodies to VEGFR‐3 to inhibit tumour metastasis and lymphangiogenesis 9. The gene discussed is FLT4; the disease is neoplasm.